Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease

Brain Research Bulletin

Volumn 88, Issue 2-3, 2012, Pages 199-209

  Giles, Peter ^a   Elliston, Lyn ^a   Higgs, Gemma V ^a   Brooks, Simon P ^a   Dunnett, Stephen B ^a   Jones, Lesley ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Behaviour; Gene expression; Huntington's disease; Neurodegeneration; Transgenic mouse models

Indexed keywords

MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; COGNITION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE PRODUCT; GENOTYPE; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RNA, MESSENGER; VISUAL CORTEX;

EID: 84860842187     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.10.001     Document Type: Article

References (51)

1. Bayram-Weston Z., Torres E.M., Jones L., Dunnett S.B., Brooks S.P. Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh((CAG)150) Huntington's disease knock-in mouse. Brain Res. Bull. 2011, [Epub ahead of print].
2. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 1995, 57:289-300.
3. Benn C.L., Fox H., Bates G.P. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol. Neurodegener. 2008, 3:17.
4. Benn C.L., Landles C., Li H., Strand A.D., Woodman B., Sathasivam K., Li S.H., Ghazi-Noori S., Hockly E., Faruque S.M., Cha J.H., Sharpe P.T., Olson J.M., Li X.J., Bates G.P. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum. Mol. Genet. 2005, 14:3065-3078.
5. K.R. Bowles, S.P. Brooks, S.B. Dunnett, L. Jones, Gene expression and behaviour in mouse models of Huntington's disease, Brain Res. Bull., in press, [Epub ahead of print].
6. Brooks S., Higgs G., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in Hdh((CAG)150) Huntington's disease knock-in mice. Brain Res. Bull. 2010, [Epub ahead of print].
7. Brooks S.P., Betteridge H., Trueman R.C., Jones L., Dunnett S.B. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease. Brain Res. Bull. 2006, 69:452-457.
8. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
9. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
10. D'Amours G., Bureau G., Boily M.J., Cyr M. Differential gene expression profiling in the mouse brain during motor skill learning: focus on the striatum structure. Behav. Brain Res. 2010, 221:108-117.
11. de Mezer M., Wojciechowska M., Napierala M., Sobczak K., Krzyzosiak W.J. Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res. 2011, 39:3852-3863.
12. Dixon K.T., Cearley J.A., Hunter J.M., Detloff P.J. Mouse Huntington's disease homolog mRNA levels: variation and allele effects. Gene Expr. 2004, 11:221-231.
13. Dragatsis I., Goldowitz D., Del Mar N., Deng Y.P., Meade C.A., Liu L., Sun Z., Dietrich P., Yue J., Reiner A. CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol. Dis. 2009, 33:315-330.
14. Dulac C. Brain function and chromatin plasticity. Nature 2010, 465:728-735.
15. Duzdevich D., Li J., Whang J., Takahashi H., Takeyasu K., Dryden D.T., Morton A.J., Edwardson J.M. Unusual structures are present in DNA fragments containing super-long Huntingtin CAG repeats. PLoS One 2011, 6:e17119.
16. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
17. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
18. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
19. Gil J.M., Rego A.C. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res. Rev. 2009, 59:410-431.
20. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., Thanos D., Kandel E.R. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002, 111:483-493.
21. Hickey M.A., Gallant K., Gross G.G., Levine M.S., Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 2005, 20:1-11.
22. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2041-2046.
23. Hodges A., Hughes G., Brooks S., Elliston L., Holmans P., Dunnett S.B., Jones L. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav. 2008, 7:288-299.
24. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L.M., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
25. J.C. Jacobsen, C.S. Bawden, S.R. Rudiger, C.J. McLaughlan, S.J. Reid, H.J. Waldvogel, M.E. MacDonald, J.F. Gusella, S.K. Walker, J.M. Kelly, G.C. Webb, R.L. Faull, M.I. Rees, R.G. Snell, An ovine transgenic Huntington's disease model, Hum. Mol. Genet. 19 (2010) 1873-1882.
26. Kim M.O., Chawla P., Overland R.P., Xia E., Sadri-Vakili G., Cha J.H. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J. Neurosci. 2008, 28:3947-3957.
27. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., Hannan A.J., Hayden M.R., Leavitt B.R., Dunnett S.B., Ferrante R.J., Albin R., Shelbourne P., Delorenzi M., Augood S.J., Faull R.L., Olson J.M., Bates G.P., Jones L., Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
28. Levenson J.M., Sweatt J.D. Epigenetic mechanisms: a common theme in vertebrate and invertebrate memory formation. Cell. Mol. Life Sci. 2006, 63:1009-1016.
29. Li J.Y., Popovic N., Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005, 2:447-464.
30. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
32. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 2002, 11:1911-1926.
33. McMurray C.T. Mechanisms of trinucleotide repeat instability during human development. Nat. Rev. Genet. 2010, 11:786-799.
34. Morton A.J., Glynn D., Leavens W., Zheng Z., Faull R.L., Skepper J.N., Wight J.M. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 2009, 33:331-341.
35. Morton A.J., Hunt M.J., Hodges A.K., Lewis P.D., Redfern A.J., Dunnett S.B., Jones L. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci. 2005, 21:855-870.
36. Quinti L., Chopra V., Rotili D., Valente S., Amore A., Franci G., Meade S., Valenza M., Altucci L., Maxwell M.M., Cattaneo E., Hersch S., Mai A., Kazantsev A. Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr. 2010, 2.
37. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:19176-19181.
38. Sadri-Vakili G., Bouzou B., Benn C.L., Kim M.O., Chawla P., Overland R.P., Glajch K.E., Xia E., Qiu Z., Hersch S.M., Clark T.W., Yohrling G.J., Cha J.H. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 2007, 16:1293-1306.
39. Smyth G.K. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments 2004.
40. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., Goldstein D.R., Matson S., Goodrich S., Markey A.L., Cormier K., Hagerty S.W., Smith K., Ryu H., Ferrante R.J. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
41. Strand A.D., Aragaki A.K., Baquet Z.C., Hodges A., Cunningham P., Holmans P., Jones K.R., Jones L., Kooperberg C., Olson J.M. Conservation of regional gene expression in mouse and human brain. PLoS Genet. 2007, 3:e59.
42. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., Beal M.F., Jones L., Kooperberg C., Olson J.M., Jones K.R. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 2007, 27:11758-11768.
43. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15545-15550.
44. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
45. Thomas E.A., Coppola G., Desplats P.A., Tang B., Soragni E., Burnett R., Gao F., Fitzgerald K.M., Borok J.F., Herman D., Geschwind D.H., Gottesfeld J.M. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15564-15569.
46. Trueman R.C., Brooks S.P., Jones L., Dunnett S.B. The operant serial implicit learning task reveals early onset motor learning deficits in the Hdh knock-in mouse model of Huntington's disease. Eur. J. Neurosci. 2007, 25:551-558.
47. von Horsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
48. Wood N.I., Morton A.J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 2003, 61:375-383.
49. Woodman B., Butler R., Landles C., Lupton M.K., Tse J., Hockly E., Moffitt H., Sathasivam K., Bates G.P. The HdhQ150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res. Bull. 2007, 72:83-97.
50. Zhou B., Xu W., Herndon D., Tompkins R., Davis R., Xiao W., Wong W.H., Toner M., Warren H.S., Schoenfeld D.A., Rahme L., McDonald-Smith G.P., Hayden D., Mason P., Fagan S., Yu Y.M., Cobb J.P., Remick D.G., Mannick J.A., Lederer J.A., Gamelli R.L., Silver G.M., West M.A., Shapiro M.B., Smith R., Camp D.G., Qian W., Storey J., Mindrinos M., Tibshirani R., Lowry S., Calvano S., Chaudry I., West M.A., Cohen M., Moore E.E., Johnson J., Moldawer L.L., Baker H.V., Efron P.A., Balis U.G., Billiar T.R., Ochoa J.B., Sperry J.L., Miller-Graziano C.L., De A.K., Bankey P.E., Finnerty C.C., Jeschke M.G., Minei J.P., Arnoldo B.D., Hunt J.L., Horton J., Cobb J.P., Brownstein B., Freeman B., Maier R.V., Nathens A.B., Cuschieri J., Gibran N., Klein M., O'Keefe G. Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9923-9928.
51. Zucker B., Luthi-Carter R., Kama J.A., Dunah A.W., Stern E.A., Fox J.H., Standaert D.G., Young A.B., Augood S.J. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 2005, 14:179-189.